Trial Profile
A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Selatogrel (Primary)
- Indications Myocardial infarction
- Focus Biomarker; Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 26 May 2020 Primary endpoint has not been met. (The response to treatment, defined for each patient as a PRU value 100 at 30 min post-dose.)
- 26 May 2020 Primary endpoint has been met. (The response to treatment, defined for each patient as a PRU value 100 at 30 min post-dose.)
- 26 May 2020 Results published in the Journal of the American College of Cardiology